Key result
Genetically proxied ACE inhibitors and CCBs protect cardiorenal health while beta-blockers worsen diabetes risk.
Why the study?
The study was conducted to systematically review Mendelian randomization studies and summarize evidence on the potential effects of different antihypertensive drugs on health.
Do genetically proxied antihypertensive drugs affect the risk of various health outcomes including cardiovascular, metabolic, and off-target diseases?
Population
37 Mendelian randomization studies evaluating antihypertensive drug classes
Comparison
Different antihypertensive drug classes vs genetically proxied exposure
Design
Systematic review of Mendelian randomization studies
Authors
Loading...
Supports ACEi/CCB preference over beta-blockers in diabetes-prone patients; extends MR evidence on antihypertensive pleiotropy.
Systematic Review (n=37)
Do genetically proxied antihypertensive drugs affect the risk of various health outcomes including cardiovascular, metabolic, and off-target diseases?
Mendelian randomization evidence supports the cardiovascular and renal benefits of ACE inhibitors and CCBs, but highlights potential off-target risks such as increased schizophrenia risk with ACE inhibitors.
Fan et al. (2024) conducted a systematic review in Various health outcomes (n=37). Antihypertensive drugs (ACE inhibitors, CCBs, BBs, etc.) was evaluated on Various health outcomes (cardiovascular diseases, kidney health, diabetes, psychiatric diseases, cancer, etc.). Genetically proxied ACE inhibitors and calcium channel blockers protected against cardiovascular diseases, diabetes, and kidney function, while beta-blockers showed adverse effects on diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: